Purdue Pharma, the controversial maker of OxyContin, faced a decisive turning point as a federal judge approved a criminal sentence that will lead to its dissolution. This move comes as part of a broader legal settlement aimed at addressing the company’s role in the opioid epidemic, which has been linked to over 900,000 deaths in the United States since 1999.

U.S. District Judge Madeline Cox Arleo delivered the sentence, saying it stemmed from a purposeful and sophisticated criminal scheme involving the sale of the opioid painkiller. Purdue Pharma is required to pay $225 million, marking an essential step in clearing the way for a settlement that resolves numerous lawsuits against the company.

During the sentencing, Judge Arleo listened to emotional testimonies from victims and families affected by the opioid crisis, many of whom pleaded for stricter penalties. Despite their emotional appeals assessing their suffering, the judge ultimately approved the negotiated sentence. She noted the lack of individual punishment, a point that left many victims dissatisfied. Alexis Pluis, a mother who lost her son to an overdose, expressed her disappointment, highlighting the challenges in proving harm from prescriptions due to bureaucratic hurdles.

As part of the settlement, members of the Sackler family, who own Purdue, agreed to pay up to $7 billion over the next 15 years. The funds are aimed at fighting the opioid crisis across various government entities. Judge Arleo criticized the Sacklers for their preferred payment schedule, suggesting they aimed to use future earnings rather than contribute out of present funds.

Purdue Pharma, based in Stamford, Connecticut, has admitted to failing to prevent the diversion of its prescription opioids to the black market. The proposed new company, Knoa Pharma, will focus on combating the opioid crisis, with a board appointed by state officials. Furthermore, millions of internal documents from Purdue are set to be made public, shedding light on the company’s practices.

This settlement marks one of the largest resolutions in a series of legal actions involving major drug manufacturers, and it includes provisions for compensation to individual victims, ranging from €8,000 to €16,000. However, many individuals fear rejection of claims due to lost medical records.

Overall, the dissolution of Purdue Pharma signifies a critical moment in the ongoing fight against the opioid epidemic, as all parties involved work to create a framework designed to prevent recurrence of such tragedies in the future.